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Background: Mycobacterium massiliense is closely related toMycobacterium abscessus and is also a frequent cause of mycobacterial lung disease
in patients with cystic ﬁbrosis (CF). There has been no previous investigation of possible differences between M. massiliense and M. abscessus
infections in the setting of CF.
Methods: We studied a prospective cohort of 16 M. massiliense and 27 M. abscessus lung infection cases with CF, with a mean follow-up of
6 years.
Results: M. massiliense cases were younger than M. abscessus cases (mean age: 12.8 vs 17.1 years; p = 0.02) at the time of the ﬁrst mycobacterial
isolation and also had lower body mass index values (mean: 16.4 vs 19.3 kg/m2, p = 0.002). All M. massiliense cases, except one, had negative
BMI Z-score values at the time of the ﬁrst mycobacterial isolation (11/12 vs 16/23 M. abscessus cases, p = 0.04). Clarithromycin-based
combination therapies led to mycobacterial eradication in 100% of M. massiliense cases but only in 27% of M. abscessus cases (p = 0.009).⁎ Corresponding author at: Laboratoire de Microbiologie, Hôpital Raymond Poincaré, 104 bld Raymond Poincaré, 92380 Garches, France. Tel.: +33 1 47 10 79 47;
fax: +33 1 47 10 79 49.
E-mail address: anne-laure.roux@rpc.aphp.fr (A.-L. Roux).
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64 A.-L. Roux et al. / Journal of Cystic Fibrosis 14 (2015) 63–69Conclusion: Our data show a particular link between M. massiliense and malnutrition speciﬁcally in CF patients. Unlike M. abscessus, the
bacteriological response of M. massiliense to combination antibiotic therapies containing clarithromycin was excellent. Distinguishing between
M. massiliense and M. abscessus has major clinical implications for CF patients.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Mycobacterium abscessus complex; Malnutrition; Nontuberculous mycobacteria; Cystic ﬁbrosis1. Introduction
Mycobacterium abscessus complex (MABSC) is in fact a
complex of three closely related “species” of rapidly growing
mycobacterium (taxonomically, they are a single species [1]):
M. abscessus sensu stricto, hereafter referred to asM. abscessus,
Mycobacterium massiliense, and Mycobacterium bolletii [2].
MABSC causes a wide spectrum of diseases in humans,
including chronic lung disease, skin disease and disseminated
disease [3]. Since the early 2000s, it has increasingly been
isolated from the respiratory tract of patients with cystic fibrosis
[4–6]. MABSC may infect CF patients at all ages, including the
very young [4,7,8]. Infection is mostly indolent and generally
progresses slowly. However, a serious, life-threatening lung
disease may develop in some patients and fatal disseminated
infections have been reported following lung transplantation
[9,10].
MABSC is one of the most antibiotic-resistant RGM: very
few drugs are potentially active, and of these, only few can be
administered by the oral route [3,11,12]. However, in vivo
selection of rrl mutants resistant to clarithromycin has been
reported and inducible resistance to clarithromycin, due to the
presence of a functional copy of erm(41), affects the majority of
M. abscessus and M. bolletii isolates [13,14].
M. abscessus and M. massiliense are responsible for N90%
of cases due to MABSC, but the relative proportions of cases
caused by the species differ between geographical regions. In
the United States and Europe, M. abscessus and M. massiliense
account for 50–60% and 30–35%, respectively, of MABSC
pulmonary isolates from both CF and non-CF patients [4,15,16].
Two studies have investigated the clinical significance of
distinguishing between the MABSC “species”, and especially
between M. abscessus and M. massiliense [16,17]. No clinical
differences were found between patients with M. abscessus
lung disease and those with M. massiliense lung disease, but
few patients were included andmost were non-CF subjects. More
recently, two large-scale retrospective studies including non-CF
adults compared the clinical characteristics and treatment
outcomes between patients with M. abscessus lung disease and
those with M. massiliense lung disease [18,19]. Consistent with
the other studies, the clinical presentations of disease caused by
the two species were similar, but the rate of response to
combination antibiotic therapy including clarithromycin was
much higher for M. massiliense than for M. abscessus.
Our main objectives were to compare M. massiliense and
M. abscessus lung diseases in CF patients and to evaluate the
benefit of distinguishingM. massiliense fromM. abscessus. We
show that M. massiliense targets young CF patients with severe
malnutrition and is associated with a better bacteriologicalresponse than M. abscessus to combination antibiotic therapies
containing clarithromycin.
2. Patients and methods
2.1. Patients included and data collection
AllM. massiliense (16) andM. abscessus (27) lung infection
cases identified in French CF patients between 2001 and 2004
were included [6]. The French multicenter prevalence study
conducted in 2004 involved 41 of 49 French CF Center and
included 1582 patients, the overall NTM prevalence was 6.6%.
Thus, risks of bias secondary to center effect were minimized.
Patients with M. bolletii infection were not included for further
study because of their small number. All cases fulfilled the
American Thoracic Society [20] bacteriological criteria for
nontuberculousmycobacteria (NTM) lung infection (i.e., positive
culture results from at least two separate expectorated sputum
samples) [21]. The mean follow-up was 6 years (extremes, 2
and 9 years). Demographic, clinical and laboratory data were
retrieved from the French CF registry, with the permission of an
Internal Review Board.
Information about occurrences of “MABSC lung disease”
(i.e., clinical and/or radiographic criteria for NTM lung infection
[21]), anti-mycobacterial treatments and treatment outcomes were
collected by chief medical officers from CF centers. MABSC
lung disease was defined by functional deterioration or new
infiltrates on thoracic imaging despite antibacterial treatment of
the sputum colonization. Constitutional symptoms were not
required. Choice of treatment was made according to the treating
physician judgment. Response to treatment was defined by the
improvement of general symptoms (fever, weight loss) if present,
improvement of pulmonary lung function tests and/or thoracic
CT scan.
2.2. Bacteriological methods
Sputum smears and mycobacterial cultures were performed
using approved techniques as previously described [8]. Identifi-
cation of “M. abscessus” and “M. massiliense” was based on
rpoB and hsp65 sequencing [22,23]; multilocus sequencing
analysis was performed in cases of discrepancy between rpoB
and hsp65 sequence data [24].
2.3. Statistical analysis
The chi-square test (or the Fisher exact test if necessary) was
used for comparisons of qualitative variables, and Student's t test
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Fig. 1. BMI Z-score in the M. massiliense and M. abscessus groups.3. Results
3.1. Characteristics of cases at the first mycobacterial isolation
M.massiliense cases (n = 16) were younger thanM. abscessus
cases (n = 27) at the time of the first mycobacterial isolation
(mean [SD] age of 12.8 [5.2] vs 17.1 [5.8] years, p = 0.02)
(Table 1). They also had lower BMI values (mean [SD] value
of 16.4 [2.3] vs 19.3 [3.1] kg/m2, p = 0.002) (Table 1); 56.3%
(9/16) had BMI values ≤16 kg/m2 vs only 14.8% (4/27) for
M. abscessus cases (p = 0.007), and a similar difference was
found for the subgroup of cases aged 10 to 18 years (64.3% [9/14]
vs 21.1% [4/19], p = 0.03). The M. massiliense and the
M. abscessus groups were otherwise similar with respect to sex
ratio, CF genotype, use of pancreatic extracts and colonization
withPseudomonas aeruginosa (Table 1). The respiratory function
evaluated with FEV1was also similar between the two groups but
we can notice that the mean FEV1 of the two groups was much
lower than mean FEV1 of the CF population at the same age
(French CF registry).3.2. Analysis of BMI Z-score data
The much lower BMI values found for the M. massiliense
group at the time of first mycobacterial isolation prompted us to
retrieve BMI Z-score data from the French CF registry. The
analysis of BMI Z-score values confirmed the previous BMI data
(Fig. 1): all M. massiliense cases, except one, had negative BMI
Z-score values at the time of the first mycobacterial isolation
whereas this was the case for only 69% of M. abscessus cases
(11/12 vs 16/23, p = 0.04).
Fig. 2 shows evolution of BMI Z-score in theM. massiliense
andM. abscessus groups. As clearly shown, the Z-score did not
decrease around the time that the mycobacteria was isolated,
and did not increase after treatment or its eradication. Thus,
malnutrition was clearly not a consequence of infection byTable 1
Characteristics of cases at first isolation of the mycobacterium.
Characteristics M. massiliense
(n = 16)
M. abscessus
(n = 27)
p-Value
M/F (sex ratio) 7/9 (0.78) 13/14 (0.93) 1
Mean [SD] age, years 12.8 [5.2] 17.1 [5.8] 0.02
F508del/F508del a 10/16 (62.5) 12/27 (44.4) 0.35
Mean [SD] BMI, kg/m2 16.4 [2.3] 19.3 [3.1] 0.002
Mean [SD] FEV1, % predicted b 64.8 [18.1]
(n = 14)
64.5 [23.7]
(n = 26)
0.96
Use of pancreatic extracts a 15/15 (100) 26/26 (100) 1
P. aeruginosa a,c 8/16 (50) 20/27 (74.1) 0.18
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in one
second.
a No./total no. evaluated (%).
b No. evaluated.
c At least one positive sample within the previous year.MABSC. We can also notice that M. massiliense, unlike
M. abscessus, affects CF patients with more severe malnutrition.
We studied the frequency of long-term enteral feeding and
parenteral feeding at the time of the first mycobacterial isolation.
The percentage of cases receiving long-term enteral feeding was
similarly low in the M. massiliense and M. abscessus groups
(2/12 [16.7%] vs 4/22 [18.2%], p = 0,91) and there was no case
of parenteral feeding in either group.3.3. Number of culture-positive samples, acid-fast bacilli (AFB)
smear positivity and occurrence of NTM lung disease
Overall, 39/43 (90%) of cases had ≥3 positive sputum
samples. The 4 cases found positive only twice were in the
M. massiliense group (4/16 vs 0/27, p = 0.01) and displayed
negative AFB smears (Fig. 3). During follow-up, 18 patients
presented symptoms of MABSC lung disease: 8 patients
presented functional deterioration (fever, asthenia, emaciation),
8 presented deterioration of their respiratory function and 9
patients presented with new pulmonary infiltrates on thoracic
imaging. M. massiliense cases tended to have less frequent
reported MABSC lung disease, but the difference between the
two groups was not significant (5/16 [31.2%] vs 13/27 [48.1%],
p = 0.35).-2,5
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Fig. 2. Kinetics of mean BMI Z-score in the M. massiliense and M. abscessus
groups. 0 is the year of the first mycobacterial isolation.
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Fig. 3. Number of positive MABSC cultures and AFB smear positivity in cases
with or without MABSC lung disease. AFB smear-positive cases were all cases
with at least one positive AFB smear. Samples were obtained for a minimum
period of 18 months. Patients with a positive NTM sample had to submit three
more sputum samples at monthly interval and then every 3 months.
Table 2
Microbiological characteristics and treatment responses for patients with
M. abscessus or M. massiliense lung disease.
M. massiliense M. abscessus p-Value
Transient colonization 4/16 0/27 0.01
Chronic colonization a 8/16 13/27 0.9
Clinical lung disease 4/16 14/27 0.08
– Antimycobacterial treatment 8/16 14/27 0.9
– Spontaneous eradication 2/7 4/12 0.8
– Eradication after treatment 6/7 3/12 0.02
a Chronic colonization is defined as more than two positive sputum with
MABSC with no clinical or radiological criteria of mycobacterial lung disease.
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positive sputum samples and all but one (17/18 [94.4%]) had
positive AFB smears (Fig. 3). However, most cases with no
evidence of MABSC lung disease also had ≥3 positive sputum
samples (21/25, 84%) with half having positive AFB smears
(12/25, 48%). Thus, indicators based on ≥3 positive samples
and positive AFB smears showed excellent negative predictive
values (100% and 92.9%, respectively), but poor positive
predictive values for MABSC lung disease (46.1% and 58.6%,
respectively).3.4. Response to antimycobacterial treatment
Twenty-two cases, 8 in the M. massiliense group (47.1%)
and 14 in the M. abscessus group (46.7%), received specific
treatment with anti-MABSC combination therapies during the
follow-up period. Four patients were treated for persistent
MABSC “colonization” without any evidence of lung disease
(3 in the M. massiliense group and 1 in the M. abscessus
group). Clarithromycin-based therapies were used in all cases but
two (one in each group), both of which received tigecycline and
amikacin. The antimicrobial agents associated with clarithromycin
were mostly amikacin (88.2%), imipenem (64.7%) and ethambu-
tol (47.1%), and more rarely trimethoprim-sulfamethoxazole
(1.2%), tobramycin, tigecyclin and linezolid (0.6% each).
Response to treatment was known for 19/22 cases
(M. massiliense, 7 cases; M. abscessus, 12 cases). MABSC was
successfully eradicated in 6/7 ofM. massiliense cases but only in
3/12 of M. abscessus cases (p = 0.02) (Table 2). Moreover,
among the cases treated with clarithromycin-based combination
therapies, MABSC was eradicated in 6/6 ofM. massiliense cases
but only in 3/11 of M. abscessus cases (p = 0.009). As clearly
shown in the Fig. 4, the treatment and the eradication of the
mycobacteria have no obvious impact on FEV1. There is a
progressive deterioration of the respiratory function in eradicated
and noneradicated CF patients over time in the M. massiliense
group and in the M. abscessus group. This progressivedeterioration of the respiratory function is also observed in
non-treated patients (data not shown).
3.5. Mortality
Three patients died, one in theM. massiliense group and two
in the M. abscessus group. The patient in the M. massiliense
group was a girl with a severe form of CF; she died when she was
ten years old in the context of Burkholderia cepacia syndrome
several years after her sole asymptomatic episode of transient
colonization with M. massiliense. One of the two deceased
patients from the M. abscessus group was a boy with repeated
positive sputum samples, but with no NTM lung disease. He died
at the age of 18 years following a lung transplant rejection 1 year
post-transplantation, with no clinical or radiological criteria of
mycobacterial lung disease. The other patient was a girl positive
for M. abscessus since the age of 20 years; lung transplantation
was not possible (contraindicated for repeated M. abscessus
positive cultures under antimycobacterial treatment) and she died
when she was 27 years old.
3.6. Lung transplantation
Five of the 43 patients included in the study (11.6%)
received lung transplants (M. abscessus, 3; M. massiliense, 2).
One of these patients, infected with M. abscessus, died from
transplant rejection 1 year post-transplantation, with no evidence
of mycobacterial disease (see above). The other four cases were
still alive 1 to 3 years after transplantation, with MABSC
eradication in two, both M. massiliense, cases.
Lung transplantation was not proposed to three patients
because sputum was culture-positive for M. massiliense (n = 1)
or M. abscessus (n = 2); these three cases included the deceased
patient described above.
4. Discussion
We here emphasize the importance of nutritional status in
M. massiliense lung disease in CF patients. Importance of
nutritional status in NTM lung disease has been previously
highlighted by several studies outside the CF context. Pulmonary
NTM lung disease in patients without predisposing condition
predominantly affects thin postmenopausal women. Mean BMI
values in North American studies ranged from 21.1 to 22.1 kg/m2
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Fig. 4. Evolution of FEV1 in treated eradicated patients and treated non-eradicated patients in the M. massiliense and M. abscessus groups. Graphs are represented
with individual curves. 0 is the year of first mycobacterial isolation.
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Weights and Standards, Hyattsville, MD) [25]. Adiponectin, an
immunosuppressive adipokine, is inappropriately secreted in
these patients [25–27]. There are several reports of NTM lung
disease in patients suffering from anorexia nervosa [28,29], in
whom impaired cellular immune response has been demonstrated
[30].
Unexpectedly, we show that M. massiliense, unlike
M. abscessus, affects young CF patients with severe malnutri-
tion. Recent studies did not find such difference in BMI values of
patients with M. massiliense or M. abscessus lung infection,
which ranged from 18.8 to 20.8 kg/m2 in Asian studies and from
22.5 to 24.4 kg/m2 in the North American study [16,18,19,31].
However, these studies were performed in non-CF adult patients
or mostly non-CF patients, suggesting that the relationship
between M. massiliense and low BMI values is specific to the
context of CF and/or to children and teenagers.
These BMI data were confirmed by the analysis of the BMI
Z-score value, a measure better adapted for evaluating malnutri-
tion, particularly in children [32]. The reason why malnutrition is
a major susceptibility factor in CF forM. massiliense, but not for
M. abscessus, remains unknown. Possibly, this may be due to
M.massiliense being less able to establish in the upper respiratory
tract. This is supported by the observation that cases of “transient
colonization” (only two positive samples with repeated subse-
quent negative cultures) were only observed within the
M. massiliense group. Also, the study of Zelazny et al. performed
in non-CF adult patients found an underlying lung disease
prior to the diagnosis of MABSC pulmonary infection in all
M. massiliense cases but only in one third of M. abscessus
cases [16].Malnutrition is a major problem in CF, and is associated with
poorer quality of life, more frequent infection and poor prognosis
[33]. The maintenance of a good nutritional status is therefore a
major goal in CF, and one of the reasons is that it increases the
median life expectancy [34]. Despite the general awareness of the
importance of nutrition in CF patients, the situation is
unsatisfactory: the CF Foundation Patient Registry in the United
States indicates that one third of patients are in urgent need of a
better nutrition [35]. Our findings are consistent with these data as
complementary enteral feeding was given to a very small
proportion of patients, especially in the M. massiliense group.
We confirm in the CF population thatM. massiliense infection,
in contrast with M. abscessus infection, responds remarkably well
to combination therapies containing clarithromycin (bacterial
eradication in 100% of cases in our study). Similar observations
were recently reported for non-CF patients in Korea [19] and in
Japan [18]. The good response ofM.massiliense to clarithromycin-
based combination therapies is probably due to this species
not having an inducible resistance to clarithromycin [14]: the
erm(41) gene, which confers inducible macrolide resistance is
non-functional in M. massiliense [36]. Note, however, that there
was clinical improvement in all cases ofM. abscessus infection in
our series treated with clarithromycin, including those with
bacteriological failure. This suggests that clarithromycin and/or
the associated antibiotics were at least partially effective in our
series. A similar discordance between clinical and bacteriological
results in non-CF patients has been described by Koh et al: 75%
of cases showed clinical improvements although the eradication
rate was only 25% [19]. Our data, and the recent findings of Koh
et al. [19] and Harada et al. [18] for non-CF patients, indicate that
clarithromycin is the cornerstone of treatment of M. massiliense
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of the ATS, which state that MABSC-positive CF patients should
not receive macrolide monotherapy to avoid the development of
resistance to clarithromycin [21].
Our findings suggest that the new cut-off of two positive
samples, as recommended in the ATS 2007 guidelines [21], is
not stringent enough for the detection of mycobacterial disease
in CF patients. Our study also confirms the prognostic value of
AFB smears. Positive AFB smears were found in 95% of the
cases of mycobacterial disease, less than 50% of those without
disease, and only 10% of those with spontaneous eradication of
mycobacteria. Thus, positive AFB smear results appear to be a
marker of the severity of the course of MABSC infections in
CF. However, caution is required in the interpretation of any
such results, and their practical value is unclear. Indeed, our
study involved mostly patients screened as part of systematic
monitoring over several years. This is a different context to that
of cases of suspected NTM lung infection for which the history
of NTM infection is not known.
The issue of lung transplantation in MABSC-positive CF
patients has been addressed in numerous case reports and studies
[7,37]. The isolation of MABSC pre-transplant is a risk factor
for the development of post-transplant NTM disease [7]. Despite
the risk of post-transplant complications, which may in some
cases be severe, lung transplantation appears to be feasible in CF
patients with MABSC infection. Our findings, albeit for a small
number of cases, support this view, as there were no cases of
post-transplant MABSC lung disease in our series. Previous
studies did not differentiate between M. massiliense and
M. abscessus. However, we found that M. massiliense cases
became negative after transplantation. Thus M. massiliense
infection should not be considered as a contraindication for
transplantation, and should be treated before transplantation with
the aim of total eradication.
Our study demonstrates that for prognostic and therapeutic
reasons, it is essential in routine practice to distinguish between
M. massiliense and M. abscessus in CF patients. Various
appropriate techniques are now available, mostly based on testing
one or more genes, for example rpoB, hsp65 and sodA [22,23].
However, the analysis of a single gene can lead to errors of
identification (for ~10% of strains) due to genetic transfer
between the two species. We recommend testing at least two
loci in the genome, and using multilocus sequencing to resolve
cases of discordant results [38]. In addition to species identifica-
tion, it is recommended that antibiotic sensitivity profile be tested
by broth microdilution techniques [21]. High-level resistance to
clarithromycin, due to rrl mutations, is easily detected, but
inducible clarithromycin resistance associated with the erm(41)
requires an extended incubation [13,14].
In conclusion, this study found clinically significant differ-
ences between M. abscessus and M. massiliense lung diseases
in CF patients. Our data point out the importance of a good
nutritional status in CF patients. In our experience, malnutrition
seems to be a key factor for M. massiliense lung disease in CF.
We are aware of the limits of this retrospective study conducted in
a limited number of patients. Thus, our results need to be
confirmed in further studies.Financial support
This work was funded by Association “Vaincre La
Mucoviscidose” (Grant no. II0341) and “Legs Poix” (Chancellerie
des Universités de Paris) (Grant no. RF201106000566).
Conﬂict of interest
All authors declare that they have no conflict of interest.
Acknowledgments
We thank Isabelle Sénégas for assistance. We thank A.
Edelman for the English revision.
References
[1] Leao SC, Tortoli E, Euzeby JP, Garcia MJ. Proposal that Mycobacterium
massiliense and Mycobacterium bolletii be united and reclassified as
Mycobacterium abscessus subsp. bolletii comb. nov., designation of
Mycobacterium abscessus subsp. abscessus subsp. nov. and emended
description of Mycobacterium abscessus. Int J Syst Evol Microbiol
2011;61:2311–3.
[2] Adekambi T, Reynaud-Gaubert M, Greub G, Gevaudan MJ, La Scola B,
Raoult D, et al. Amoebal coculture of "Mycobacterium massiliense" sp.
nov. from the sputum of a patient with hemoptoic pneumonia. J Clin
Microbiol 2004;42:5493–501.
[3] Jonsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-
Olsson C. Molecular Epidemiology of Mycobacterium abscessus, with
Focus on Cystic Fibrosis. J Clin Microbiol 2007;45:1497–504.
[4] Esther Jr CR, Henry MM, Molina PL, Leigh MW. Nontuberculous
mycobacterial infection in young children with cystic fibrosis. Pediatr
Pulmonol 2005;40:39–44.
[5] Olivier KN, Weber DJ, Wallace Jr RJ, Faiz AR, Lee JH, Zhang Y, et al.
Nontuberculous mycobacteria. I: multicenter prevalence study in cystic
fibrosis. Am J Respir Crit Care Med 2003;167:828–34.
[6] Roux AL, Catherinot E, Rippoll F, Soismier N, Macheras E, Ravilly S,
et al. Multicenter French prevalence study of non tuberculous
mycobacteria in cystic fibrosis. J Clin Microbiol 2009;47:4124–8.
[7] Chalermskulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera
MP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis:
implications for lung transplantation. Thorax 2006;61:507–13.
[8] Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, Le Bourgeois M,
Offredo C, Vu-Thien H, et al. Age-related prevalence and distribution of
nontuberculous mycobacterial species among patients with cystic fibrosis.
J Clin Microbiol 2005;43:3467–70.
[9] Brown-Elliott BA, Wallace Jr RJ. Clinical and taxonomic status of
pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.
Clin Microbiol Rev 2002;15:716–46.
[10] Sanguinetti M, Ardito F, Fiscarelli E, La Sorda M, D'Argenio P, Ricciotti
G, et al. Fatal pulmonary infection due to multidrug-resistant Mycobac-
terium abscessus in a patient with cystic fibrosis. J Clin Microbiol
2001;39:816–9.
[11] Griffith DE, Aksamit TR. Therapy of refractory nontuberculous
mycobacterial lung disease. Curr Opin Infect Dis 2012;25:218–27.
[12] Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium
abscessus: a new antibiotic nightmare. J Antimicrob Chemother
2012;67:810–8.
[13] Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, et al.
Assessment of clarithromycin susceptibility in strains belonging to the
Mycobacterium abscessus group by erm(41) and rrl sequencing.
Antimicrob Agents Chemother 2011;55:775–81.
[14] Nash KA, Brown-Elliott BA, Wallace Jr RJ. A novel gene, erm(41),
confers inducible macrolide resistance to clinical isolates of
69A.-L. Roux et al. / Journal of Cystic Fibrosis 14 (2015) 63–69Mycobacterium abscessus but is absent from Mycobacterium chelonae.
Antimicrob Agents Chemother 2009;53:1367–76.
[15] Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR,
et al. Respiratory outbreak of Mycobacterium abscessus subspecies
massiliense in a lung transplant and cystic fibrosis center. Am J Respir
Crit Care Med 2012;185:231–2.
[16] Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F,
et al. Cohort study of molecular identification and typing of Mycobac-
terium abscessus, Mycobacterium massiliense, and Mycobacterium
bolletii. J Clin Microbiol 2009;47:1985–95.
[17] van Ingen J, de Zwaan R, Dekhuijzen RP, Boeree MJ, van Soolingen D.
Clinical relevance of Mycobacterium chelonae-abscessus group isolation
in 95 patients. J Infect 2009;59:324–31.
[18] Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T,
et al. Clinical and microbiological differences between Mycobacterium
abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol
2012;50:3556–61.
[19] Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Clinical
significance of differentiation of Mycobacterium massiliense from
Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405–10.
[20] Chopra S, Matsuyama K, Hutson C, Madrid P. Identification of
antimicrobial activity among FDA-approved drugs for combating
Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob
Chemother 2011;66:1533–6.
[21] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin
F, et al. An official ATS/IDSA statement: diagnosis, treatment, and
prevention of nontuberculous mycobacterial diseases. Am J Respir Crit
Care Med 2007;175:367–416.
[22] Adekambi T, Colson P, Drancourt M. rpoB-based identification of
nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin
Microbiol 2003;41:5699–708.
[23] Ringuet H, Akoua-Koffi C, Honore S, Varnerot A, Vincent V, Berche P,
et al. hsp65 sequencing for identification of rapidly growing mycobacteria.
J Clin Microbiol 1999;37:852–7.
[24] Macheras E, Roux AL, Bastian S, Leão SC, Palaci M, Sivadon-Tardy V,
et al. Multilocus sequence analysis and rpoB sequencing of Mycobacte-
rium abscessus (sensu lato) strains. J Clin Microbiol 2011;49:491–9.
[25] Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J,
et al. Patients with nontuberculous mycobacterial lung disease exhibit
unique body and immune phenotypes. Am J Respir Crit Care Med
2013;187:197–205.
[26] Chan ED, Iseman MD. Slender, older women appear to be more
susceptible to nontuberculous mycobacterial lung disease. Gend Med
2010;7:5–18.[27] Tasaka S, Hasegawa N, Nishimura T, Yamasawa W, Kamata H, Shinoda
H, et al. Elevated serum adiponectin level in patients with Mycobacterium
avium-intracellulare complex pulmonary disease. Respiration
2010;79:383–7.
[28] Brown GR. Anorexia nervosa complicated by Mycobacterium xenopi
pulmonary infection. J Nerv Ment Dis 1987;175:629–32.
[29] Cosson MA, Bertrand JB, Martin C, Veziris N, Picard C, Goulvestre C,
et al. Temporal interferon-gamma release response to Mycobacterium
kansasii infection in an anorexia nervosa patient. J Med Microbiol
2012;61:1617–20.
[30] Nova E, Samartin Gomez S, Morandé G, Marcos A. The adaptive
response of the immune system to the particular malnutrition of eating
disorders. Eur J Clin Nutr 2002;56(Suppl. 3):S34–7.
[31] Shin SJ, Choi GE, Cho SN, Woo SY, Jeong BH, Jeon K, et al.
Mycobacterial genotypes are associated with clinical manifestation and
progression of lung disease caused by Mycobacterium abscessus and
Mycobacterium massiliense. Clin Infect Dis 2013;57:32–9.
[32] Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG,
et al. Growth status in children with cystic fibrosis based on the National
Cystic Fibrosis Patient Registry data: evaluation of various criteria used to
identify malnutrition. J Pediatr 1998;132:478–85.
[33] Steinkamp G, Wiedemann B. Relationship between nutritional status and
lung function in cystic fibrosis: cross sectional and longitudinal analyses
from the German CF quality assurance (CFQA) project. Thorax
2002;57:596–601.
[34] Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and
survival in the UK: 1947-2003. Eur Respir J 2007;29:522–6.
[35] U.S. Cystic Fibrosis Foundation. The Cystic Fibrosis Patient Registry:
Annual data report 2011. Available from: www.cff.org.
[36] Kim HY, Kim BJ, Kook Y, Yun YJ, Shin JH, Kim BJ, et al.
Mycobacterium massiliense is differentiated from Mycobacterium
abscessus and Mycobacterium bolletii by erythromycin ribosome
methyltransferase gene (erm) and clarithromycin susceptibility patterns.
Microbiol Immunol 2010;54:347–53.
[37] Gilljam M, Schersten H, Silverborn M, Jönsson B, Ericsson Hollsing A.
Lung transplantation in patients with cystic fibrosis and Mycobacterium
abscessus infection. J Cyst Fibros 2010;9:272–6.
[38] Macheras E, Roux AL, Ripoll F, Sivadon-Tardy V, Gutierrez C,
Gaillard JL, et al. Inaccuracy of single-target sequencing for discrim-
inating species of the Mycobacterium abscessus group. J Clin Microbiol
2009;47:2596–600.
